Literature DB >> 2561214

SC-41930: an inhibitor of leukotriene B4-stimulated human neutrophil functions.

B S Tsai1, D Villani-Price, R H Keith, J M Zemaitis, R F Bauer, R Leonard, S W Djuric, R L Shone.   

Abstract

SC-41930 was evaluated for effects on human neutrophil chemotaxis and degranulation. At concentrations up to 100 microM, SC-41930 alone exhibited no effect on neutrophil migration, but dose-dependently inhibited neutrophil chemotaxis induced by leukotriene B4 (LTB4) in a modified Boyden chamber. Concentrations of SC-41930 from 0.3 microM to 3 microM competitively inhibited LTB4-induced chemotaxis with a pA2 value of 6.35. While inactive at 10 microM against C5a-induced chemotaxis, SC-41930 inhibited N-formyl-methionyl-leucyl-phenylalanine (fMLP)-induced chemotaxis, with 10 times less potency than against LTB4-induced chemotaxis. SC-41930 inhibited [3H]LTB4 and [3H]fMLP binding to their receptor sites on human neutrophils with KD values of 0.2 microM and 2 microM, respectively. SC-41930 also inhibited neutrophil chemotaxis induced by 20-OH LTB or 12(R)-HETE. At concentrations up to 10 microM, SC-41930 alone did not cause neutrophil degranulation, but inhibited LTB4-induced degranulation in a noncompetitive manner. SC-41930 also inhibited fMLP- or C5a-induced degranulation, but was about 8 and 10 times less effective for fMLP and C5a, respectively. The results indicate that SC-41930 is a human neutrophil LTB4 receptor antagonist with greater specificity for LTB4 than for fMLP or C5a receptors.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2561214     DOI: 10.1016/0090-6980(89)90048-8

Source DB:  PubMed          Journal:  Prostaglandins        ISSN: 0090-6980


  6 in total

1.  Effect of BRL-35135 on LTB4-induced guinea pig eosinophil chemotaxis.

Authors:  T Sugasawa; S Morooka
Journal:  Agents Actions       Date:  1992-11

2.  Modulation of the chemotactic properties of complement fragments C5a and C3 by the anti-inflammatory agent, SC-41930.

Authors:  D J Fretland; D L Widomski; C P Anglin; S Levin; T S Gaginella
Journal:  Agents Actions       Date:  1991-09

3.  The design and synthesis of second generation leukotriene B4 (LTB4) receptor antagonists related to SC-41930.

Authors:  T D Penning; S W Djuric; S H Docter; S S Yu; D Spangler; C P Anglin; D J Fretland; J F Kachur; R H Keith; B S Tsai
Journal:  Agents Actions       Date:  1993

4.  Mucosal factors inducing neutrophil movement in ulcerative colitis: the role of interleukin 8 and leukotriene B4.

Authors:  A T Cole; B J Pilkington; J McLaughlan; C Smith; M Balsitis; C J Hawkey
Journal:  Gut       Date:  1996-08       Impact factor: 23.059

5.  The Role of PPARgamma Receptors and Leukotriene B(4) Receptors in Mediating the Effects of LY293111 in Pancreatic Cancer.

Authors:  Thomas E Adrian; Rene Hennig; Helmut Friess; Xianzhong Ding
Journal:  PPAR Res       Date:  2009-01-27       Impact factor: 4.964

6.  Combined Analysis of the Aberrant Epigenetic Alteration of Pancreatic Ductal Adenocarcinoma.

Authors:  Rui Xu; Qiuyan Xu; Guanglei Huang; Xinhai Yin; Jianguo Zhu; Yikun Peng; Jukun Song
Journal:  Biomed Res Int       Date:  2019-12-28       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.